Recombinant Human PSMA/FOLH1/NAALADase I His Protein, CF

R&D Systems, part of Bio-Techne | Catalog # BT4234

Biotinylated
R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
BT4234-010
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

CHO

Accession #

NP_004467.1

Structure / Form

Biotinylated via amines.

Conjugate

Biotin

Applications

Binding Activity, Enzyme Activity

View all PSMA/FOLH1/NAALADase I Proteins and Enzymes »

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human PSMA/FOLH1/NAALADase I protein
Lys44-Ala750 with an N-terminal 6-His tag

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

His

Predicted Molecular Mass

80 kDa

SDS-PAGE

94-104 kDa, under reducing conditions

Activity

Measured by its ability to hydrolyze the substrate N-acetyl-L-Asp-L-Glu into N-acetyl-L-Asp and L-Glu. The L-Glu product is measured by fluorescence after its derivatization by ortho-phthaldialdehyde.
The specific activity is >250 pmol/min/μg, as measured under the described conditions.

Measured by its binding ability in a functional ELISA.
Biotinylated Recombinant Human PSMA/FOLH1/NAALADase I (Catalog # BT4234) binds Human PSMA/FOLH1/NAALADase I Antibody (Catalog # MAB4234) with an ED50 of 50.0-600 ng/mL.

Scientific Data Images for Recombinant Human PSMA/FOLH1/NAALADase I His Protein, CF

Biotinylated Recombinant Human PSMA/FOLH1/ NAALADase I Protein Binding Activity.

Biotinylated Recombinant Human PSMA/FOLH1/ NAALADase I Protein (Catalog # BT4234) binds Human PSMA/FOLH1/NAALADase I Antibody (MAB4234) with an ED50 of 50.0-600 ng/mL.

Biotinylated Recombinant Human PSMA/FOLH1/ NAALADase I Protein SDS-PAGE.

2 μg/lane of Biotinylated Recombinant Human PSMA/FOLH1/NAALADase I Protein (Catalog # BT4234) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 94-104 kDa, under reducing conditions.

Formulation, Preparation and Storage

BT4234
Formulation Supplied as a 0.2 μm filtered solution in MES and NaCl.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -70 °C as supplied.
  • 3 months, -70 °C under sterile conditions after opening.

Background: PSMA/FOLH1/NAALADase I

Prostate-specific membrane antigen (PSMA), a tumor marker in prostate cancer encoded by the FOLH1 gene, is a type II transmembrane zinc metallopeptidase that is most highly expressed in the nervous system, prostate, kidney, and small intestine (1,2). PMSA has a short cytosolic N-terminal domain, a single membrane-spanning segment, and an extracellular region that is composed of a protease domain, apical domain, and C-terminal domain (3). The extracellular domains all contribute to substrate recognition. The protein forms an active homodimer reliant on interactions between amino-acid side chains and glycosylation (3,4). PSMA is also known as glutamate carboxypeptidase II (GCPII), folate hydrolase 1, and N-acetylated-alpha-linked acidic dipeptidase-1 (NAALADase1). PSMA activity plays a role in tumor angiogenesis making it not only a tumor marker, but a therapeutic target in cancers including prostate cancer (5). In the brain, PSMA hydrolyzes the neurotransmitter N-acetyl-Asp-Glu (NAAG) to produce glutamate, another neurotransmitter. Inhibition of brain PSMA activity is considered to be a promising approach for the treatment of neurological disorders associated with glutamate excitotoxicity such as stroke, schizophrenia, Alzheimer's, and amyotrophic lateral sclerosis (6,7,8). Intestinal PSMA hydrolyzes folylpoly-gamma -glutamates, facilitating the uptake of folate (8). Upregulation of PSMA is present in inflammatory bowel disease, Crohn's disease, and ulcerative colitis where pharmacological inhibition has shown amelioration of clinical symptoms pertaining to these diseases in mice (5).

References

  1. Silver, D.A. et. al. (1997) Clin. Cancer Res. 3:81.
  2. Carter, R.E. et. al. (1996) Pro. Natl. Acad. Sci. USA. 93:749.
  3. Mesters, J.R. et. al. (2006) EMBO J. 25:1375.
  4. Shulke, N. et. al. (2003) Proc. Natl. Acad. Sci. USA 100:12590.
  5. Vornov, J.J. et. al. (2020) Neurochem. Res. 45:1256.
  6. Jackson, P.F. and Slusher, BS (2001) Curr. Med. Chem. 8:949.
  7. Neale, J.J. and T Yamamoto. (2020) Prog. Neurobiol. 184:101722.
  8. Heston, W.D. (1997) Urology 49:104.

Long Name

Prostate-specific Membrane Antigen

Alternate Names

FGCP, FOLH1, GCP2, GCPII, mopsm, NAALAD1, NAALADase I

Entrez Gene IDs

2346 (Human); 53320 (Mouse); 85309 (Rat); 101866140 (Cynomolgus Monkey)

Gene Symbol

FOLH1

UniProt

NP_004467.1

Additional PSMA/FOLH1/NAALADase I Products

Product Documents for Recombinant Human PSMA/FOLH1/NAALADase I His Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human PSMA/FOLH1/NAALADase I His Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.